PTC Therapeutics' Huntington's Treatment Gets FDA Fast Track Designation
By Adriano Marchese
PTC Therapeutics' treatment for Huntington's disease has received a fast track designation from U.S. health regulators.
The biopharmaceutical company said Thursday that the Food and Drug Administration granted the designation to the PTC518 program which aims to reduce the production of mutated Huntington protein.
Huntington's disease is a fatal, hereditary, genetic disorder that affects the central nervous system. Due to a defective gene, an abnormal, toxic protein is produced in the body called Huntington protein that damages and kills neurons.
PTC518 was discovered through the development of another drug, Risdiplam, which treats spinal muscular atrophy. In June of this year, PTC518 received positive results from interim data from its Pivot-HD study of the drug in patients with the disease.
With the fast track designation, PTC will be able to develop the treatment quicker and receive a faster review from the FDA.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
September 26, 2024 08:58 ET (12:58 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now